About Sonnet Biotherapeutics

Sonnet Biotherapeutics (NASDAQ:SONN) is a biopharmaceutical company engaged in developing innovative therapies with a focus on oncological and immunological conditions. Leveraging its proprietary Fully Human Albumin Binding (F H AB) technology, Sonnet aims to create biologic drugs with enhanced efficacy and reduced toxicity, providing new treatment options for patients suffering from severe diseases. The company is committed to advancing its pipeline through rigorous scientific research, strategic collaborations, and clinical development programs. Its objective is to address unmet medical needs by bringing forth novel therapeutics that can offer meaningful improvements in patients' lives.

Snapshot

Public USOwnership

1999Year founded

12Employees

Charlotte, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

United States

Products and/or services of Sonnet Biotherapeutics

SON-1010 (IL-12Fc): A fusion protein for cancer treatment, leveraging interleukin-12 to boost the immune system's ability to fight tumors.
SON-1210 (IL-15Fc): Focuses on enhancing the body's natural killer (NK) and T cells' capabilities against cancer through an interleukin-15 fusion protein.
SON-081 (Low Dose IL-6): Developed for the treatment of peripheral neuropathy, specifically targeting diabetic peripheral neuropathy through low dose interleukin-6.
SON-080 (Low Dose IL-6): Aimed at treating chemotherapy-induced peripheral neuropathy, utilizing a low dose of interleukin-6 to mitigate symptoms.
Bispecific Antibody Therapies: Innovative therapies combining two different antibodies to target multiple cancer pathways simultaneously.
Immunotherapy Platforms: Advanced technology platforms designed to enhance the development of next-generation immunotherapies for cancer.

Sonnet Biotherapeutics executive team

Mr. Raghu RaoInterim CEO & Director
Dr. John K. Cini Ph.D.Chief Scientific Officer & Co-Founder
Mr. Donald J. Griffith CPA, CPACFO & Director
Dr. Stephen J. McAndrew Ph.D.President & Chief Business Officer
Dr. Gael Hedou Ph.D.Chief Operating Officer
Ms. Susan DexterChief Technical Officer
Dr. Richard T. Kenney FACP, M.D.Chief Medical Officer
Mr. Manuel DafonsecaHead of Clinical Operations